(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
26 April 2007 (26.04.2007)

PCT

(10) International Publication Number
WO 2007/047995 A3

(51) International Patent Classification:
*A61K 38/48* (2006.01) *C12N 15/86* (2006.01)
*C12N 9/64* (2006.01) *C12N 5/10* (2006.01)
*C12N 15/62* (2006.01)

(21) International Application Number:
PCT/US2006/041165

(22) International Filing Date: 20 October 2006 (20.10.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/729,817 21 October 2005 (21.10.2005) US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:
US 60/729,817 (CON)
Filed on 21 October 2005 (21.10.2005)

(71) Applicant *(for all designated States except US)*: **CATALYST BIOSCIENCES, INC.** [US/US]; 260 Littlefield Avenue, South San Francisco, CA 94080 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **MADISON, Edwin, L.** [US/US]; 290 Utah Avenue, South San Francisco, CA 94080 (US). **NGUYEN, Jack** [US/US]; 290 Utah Avenue, South San Francisco, CA 94080 (US). **RUGGLES, Sandra, Waugh** [US/US]; 290 Utah Avenue, South San Francisco, CA 94080 (US). **THANOS, Christopher, D.** [US/US]; 250 Pt. Lobos Avenue, Pat. 504, San Francisco, CA 94121 (US).

(74) Agents: **SEIDMAN, Stephanie, L.** et al.; Fish & Richardson P.C., 12390 El Camino Real, San Diego, CA 92130 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US (patent), UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

**Published:**
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*
— *with sequence listing part of description published separately in electronic form and available upon request from the International Bureau*

(88) Date of publication of the international search report:
4 October 2007

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: MODIFIED PROTEASES THAT INHIBIT COMPLEMENT ACTIVATION

(57) Abstract: Provided are methods for and compounds for modulating the complement system. In particular, compounds are provided that inhibit complement activation and compounds are provided that promote complement activation. The compounds are therapeutics by virtue of their effects on the complement system. Hence, the compounds that inhibit complement activation can be used for treatment of ischemic and reperfusion disorders, including myocardial infarction and stroke, sepsis, autoimmune diseases, inflammatory diseases and diseases with an inflammatory component, including Alzheimer's Disease and other neurodegenerative disorder.

WO 2007/047995 A3